ABL Diagnostics wins court approval to acquire TEXCELL operations

ABL Diagnostics has been selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations, a move that expands the French diagnostics group in virology, biosafety and infectious disease services. The deal keeps operations at Genopole in Évry-Courcouronnes, transfers 29 employees and is being financed from ABL Diagnostics’ available resources.

Why it matters: - The acquisition gives ABL Diagnostics a stronger foothold in virology, biosafety and biological control, alongside its molecular diagnostics business. - The deal preserves TEXCELL’s operations and jobs while keeping activity at the Genopole site in Évry-Courcouronnes. - ABL Diagnostics also gains scientific assets that could support new tools for biomedical research, quality control and molecular diagnostics.

What happened: - The Évry Commercial Court selected ABL Diagnostics to acquire TEXCELL’s assets and business operations. - The decision followed an industrial plan from ABL Diagnostics focused on business continuity, scientific expertise and fit with its existing activities in molecular diagnostics, virology and infectious diseases. - The acquisition includes TEXCELL’s strategic assets, transferred commercial contracts and continued operations at Genopole. - The transaction also transfers 29 employees, including 23 permanent staff and 6 apprentices or trainees. - ABL Diagnostics will assume accrued employee rights tied to the transferred workers for €91,829.24, subject to final adjustment.

The details: - TEXCELL emerged from the Institut Pasteur scientific ecosystem and has expertise in viral safety, biosafety, genomic analysis, immunological monitoring and services for biotechnology and innovative therapies. - Publicly available information shows TEXCELL France generated about €5.4 million of revenue in 2024, down from €6.2 million in 2023 and €7.5 million in 2022. - The overall economic value of the project is estimated at about €2.9 million. - The deal includes a €225,000 asset purchase price, split between €165,000 of intangible assets and €60,000 of tangible assets. - ABL Diagnostics will acquire inventories for a lump-sum €30,000 excluding VAT. - The company will reconstitute security deposits of about €100,000. - The deal covers lease financing agreements tied to operational equipment, including future lease payments of €531,792.74, subject to final adjustment. - ABL Diagnostics plans an industrial and technological investment program of €930,000. - The company estimates an increase in working capital needs of €1 million to support the acquired activities. - ABL Diagnostics said the transaction will be financed from the group’s available financial resources. - The accepted offer’s terms are set out in documents filed with the Évry Commercial Court. - The acquisition adds an operational presence for ABL Diagnostics within Genopole Évry-Courcouronnes. - ABL Diagnostics plans to add about five more employees to support the scientific activities inherited from TEXCELL.

Between the lines: - The move extends ABL Diagnostics’ broader strategic tie-up with the Institut Pasteur, following a recent HPV RNA-Seq genotyping project in Paris. - TEXCELL’s origins in the Institut Pasteur ecosystem make the acquisition a strategic fit for ABL Diagnostics’ focus on innovation, virology and infectious diseases. - TEXCELL’s strengths in viral safety, biological control, cell culture, viral characterization and biosafety complement ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - The company is not just buying revenue; it is buying specialized expertise, infrastructure and a recognized brand in a niche scientific market. - The planned investment in automation, infrastructure modernization and hiring suggests ABL Diagnostics intends to integrate TEXCELL as a growth platform rather than a standalone rescue asset.

What's next: - ABL Diagnostics said further details will follow after completion of legal and administrative formalities. - The company plans to share more on integration of the acquired activities and how they fit into its strategic roadmap and 2026 objectives. - Forward-looking statements in the release remain subject to risks and uncertainties, including legal proceedings and third-party approvals.

The bottom line: - ABL Diagnostics is using a court-approved acquisition to deepen its push into virology and infectious diseases while preserving TEXCELL’s scientific base and expanding its presence at Genopole.